Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of investigational MMRV vaccine vs ProQuad in children 4–6 years
2022-501564-18-00Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, single-blind trial of GSKVX000000025896 in measles, mumps, rubella and 1 more (4 arms), sponsored by GSK. Primary endpoints: Anti-measles antibody geometric mean concentrations (GMCs) at Day 43, Anti-mumps antibody geometric mean concentrations (GMCs) at Day 43 and 2 more. Started Apr 2023; status: completed.
02
Drugs
GSKVX000000025896
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2022-501564-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501564-18-00.